Funded Research

Identifying a Clinically Available PDE4 Inhibitor for Treatment of Children with Malignant Brain Tumors
Principal Investigator(s):
Status:
Completed
Center(s):
  • McDonnell Pediatric Cancer Center
Award Mechanism:
Large-Scale Interdisciplinary Research Initiative
Project Period:
7/1/2008 - 6/30/2011
Total Amount:
$50,000
It has been found that inhibition of PDE4 with the drug Rolipram can be safely combined with standard chemotherapy and radiation therapy for the treatment of mice with malignant brain tumors. Moreover, this combined therapy displayed an unprecedented therapeutic effect on highly malignant model glioblastomas, in which tumors were seen to completely regress. Rolipram is not clinically available at present but there are several other PDE4 inhibitors curently in clinical trial for chronic obstructive pulmonary disease and asthma. Because of this CDI award, Dr. Rubin will be able to screen a subset of these drugs to determine whether there are any with similar activity to Rolipram. From there, a clinical trial will follow.